First Daily Pill From the GLP-1 Family Significantly Reduces Sleep Apnea Severity in Two Phase 3 Trials
Two Phase 3 trials found that orforglipron, an oral GLP-1 medication, cut breathing interruptions by roughly four times as much as placebo in adults with obstructive sleep apnea and obesity or overweight, with benefits seen whether or not patients also used CPAP.